MDDX Trademark

Trademark Overview

On Tuesday, October 18, 2022, a trademark application was filed for MDDX with the United States Patent and Trademark Office. The USPTO has given the MDDX trademark a serial number of 97637096. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Thursday, July 24, 2025. This trademark is owned by MDDx, Inc.. The MDDX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research in the field of biologic, proteomic, and genetic analysis for the susceptibility, response to treatment, and recurrence of cancer and other diseases
mddx

General Information

Serial Number97637096
Word MarkMDDX
Filing DateTuesday, October 18, 2022
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateThursday, July 24, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesMedical and scientific research in the field of biologic, proteomic, and genetic analysis for the susceptibility, response to treatment, and recurrence of cancer and other diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, November 2, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMDDx, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591

Trademark Events

Event DateEvent Description
Tuesday, August 1, 2023NON-FINAL ACTION E-MAILED
Friday, October 21, 2022NEW APPLICATION ENTERED
Wednesday, November 2, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 1, 2023ASSIGNED TO EXAMINER
Tuesday, August 1, 2023NON-FINAL ACTION WRITTEN
Tuesday, August 1, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 1, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 1, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 2, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 25, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, November 30, 2023SUSPENSION LETTER WRITTEN
Thursday, November 30, 2023LETTER OF SUSPENSION E-MAILED
Thursday, November 30, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, January 24, 2025NON-FINAL ACTION WRITTEN
Friday, January 24, 2025NON-FINAL ACTION E-MAILED
Friday, January 24, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 18, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, July 24, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 24, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 24, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 18, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

Related Keywords

mddx treatment response recurrence cancer diseases other susceptibility analysis research scientific